

# PATENT ASSIGNMENT

Electronic Version v1.1

Stylesheet Version v1.1

<b>SUBMISSION TYPE:</b>	CORRECTIVE ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	Corrective Assignment to correct the 12/808326 previously recorded on Reel 024692 Frame 0466. Assignor(s) hereby confirms the 12/808346.
<b>CONVEYING PARTY DATA</b>	
Name	Execution Date
Argenta Discovery 2009 Limited	09/07/2010
<b>RECEIVING PARTY DATA</b>	
Name:	Genentech, Inc.
Street Address:	1 DNA Way
Internal Address:	MS49
City:	South San Francisco
State/Country:	CALIFORNIA
Postal Code:	94080
<b>PROPERTY NUMBERS Total: 4</b>	
Property Type	Number
Application Number:	12808346
PCT Number:	US0887476
Application Number:	61015155
Application Number:	61054024
<b>CORRESPONDENCE DATA</b>	
Fax Number:	(650)952-9881
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	6502241000
Email:	trenshaw@gene.com
Correspondent Name:	Genentech, Inc.
Address Line 1:	1 DNA Way
Address Line 2:	MS49
Address Line 4:	South San Francisco, CALIFORNIA 94080
<b>ATTORNEY DOCKET NUMBER:</b>	P4149R1 CORRECTIVE ASSGN

CH \$160.00 12808346

501623787

**PATENT**  
**REEL: 026735 FRAME: 0730**

NAME OF SUBMITTER:

Brian L. Buckwalter

Total Attachments: 2

source=P4149R1\_Assignment\_Argenta\_to\_Genentech#page1.tif

source=P4149R1\_Assignment\_Argenta\_to\_Genentech#page2.tif

**A S S I G N M E N T**

WHEREAS, ARGENTA DISCOVERY 2009 LIMITED, a company registered in England with number 3671653, whose registered office and principal place of business is 8/9 Spire Green Centre, Flex Meadow, Harlow, Essex CM195TR (hereinafter "ASSIGNOR") has full right, title, and interest in and to a new and useful invention in:

8 ANILINOIMIDAZOPYRIDINES AND THEIR USE AS ANTI-CANCER AND/OR  
ANTI-INFLAMMATORY AGENTS

for which US application No. 12/808,346 (Docket No. P4149R1 US) for Letters Patent has been by them on June 15, 2010, and International Application No. PCT/US2008/087476 (Docket No. P4149R1) was filed by them on December 18, 2008, and US Provisional Application No. 61/015,155 (Docket No. PR4149) was filed by them on December 19, 2007, and US Provisional Application No. 61/054,024 (Docket No. PR4149-1) was filed by them on May 16, 2008; and

WHEREAS, GENENTECH, INC., a corporation organized and existing under and by virtue of the laws of the State of Delaware, having a place of business at 1 DNA Way, South San Francisco, California 94080-4990, is desirous of acquiring an interest in and to said invention, and in and to the Letters Patents to be obtained therefor;

NOW, THEREFORE, be it known by all whom it may concern;

That for good and valuable consideration the receipt of which is hereby acknowledged, the said ASSIGNORS have and do hereby sell, assign, transfer and set over unto the said GENENTECH, INC., its successors and assigns, the full and exclusive right, title and interest including all rights under the Paris Convention for the Protection of Industrial Property, in and to said invention, and in and to any and all Letters Patents to be granted and issued therefor or any continuation, division, renewal, or substitute thereof, and as to Letters Patents any reissue or re-examination thereof, not only for, to, and in the United States of America, its territories and possessions, but for, to and in all other countries; and it has been and is hereby authorized and requested that the appropriate government agencies issue said Letters Patents to said GENENTECH, INC., in accordance with this Assignment.

Said ASSIGNORS covenant and agree to cooperate with GENENTECH, INC., to enable said GENENTECH, INC. to enjoy to the fullest extent the right, title and interest herein conveyed in the United States and foreign countries. Such cooperation by said ASSIGNORS includes prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by said GENENTECH, INC., (a) for perfecting the right, title and interest herein conveyed; (b) for prosecuting any of said applications; (c) for filing and prosecuting applications for reissuance of any of said patents; (d) for interference or other priority proceedings involving said invention; and (e) for legal proceedings involving said invention and any applications therefor and any patents granted thereon, including without limitation opposition proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions; provided, however, that the expense incurred by said ASSIGNORS in providing such cooperation shall be paid for by said GENENTECH, INC.


The terms and covenants of this assignment shall inure to the benefit of said GENENTECH, INC., its successors, assigns and other legal representatives, and shall be binding upon said ASSIGNORS, their respective heirs, legal representatives and assigns.

Said ASSIGNORS hereby warrant and represent that they have not entered and will not enter into any assignment, contract, or understanding in conflict herewith.

IN WITNESS WHEREOF we undersign as follows;

Essex, United Kingdom

Dated: 9/7/10

  
\_\_\_\_\_  
Dr. John Montana  
For and on behalf of  
Argenta Discovery 2009 Limited